Nav: Home

Global study shows new breast cancer drug extends patients' overall survival

June 05, 2004

NEW ORLEANS- Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study presented today at the American Society of Clinical Oncology (ASCO) annual meeting.

"Improved overall survival demonstrates that gemcitabine with paclitaxel should be a standard frontline regimen in treating breast cancer that has spread," said principal investigator and first author Dr. Kathy S. Albain, professor, division of hematology/oncology, Department of Medicine, Loyola University Chicago Stritch School of Medicine, Maywood, Ill.

Albain designed and chaired this international trial that directly resulted in the FDA's very recent approval of gemcitabine for breast cancer. In previous years, the FDA has approved gemcitabine for other cancers. The drug disrupts cell replication by incorporating itself directly into the DNA.

The research applies to women who have never had chemotherapy for their advanced breast cancer but were already exposed to the anticancer class of drugs known as anthracyclines when their breast cancer was first diagnosed in an early stage.

Participating in the study were 529 patients randomized at 98 sites in 19 countries. The study compared gemcitabine plus paclitaxel to paclitaxel alone in women with metastatic breast cancer.

A total of 267 patients (median age: 53 years) received gemcitabine plus paclitaxel; another 262 patients (median age: 52 years) received paclitaxel alone. Albain reported that median overall survival was 18.5 months for gemcitabine with paclitaxel, and 15.8 months for paclitaxel alone.

"One year survival was 71 percent in the group that received the combination therapy, compared to 61 percent for the group treated with paclitaxel alone," said Albain, director, Breast Research Program; co-director of the multidisciplinary Breast Oncology Center; and director of the Thoracic Oncology Program, Cardinal Bernardin Cancer Center, Loyola University Health System, Maywood, Ill. The gemcitabine plus paclitaxel combination resulted in a 26 percent reduction in breast cancer deaths when all other factors were taken into account.

"These results are important because it was uncertain if earlier findings would translate into overall survival benefit," said Albain. "Now, we know they do."

Last year's results showed that the drug combination therapy significantly slowed the rate of tumor progression and improved patient quality of life.

That research also found that gemcitabine provided pain relief in symptomatic patients.

"Today's interim overall survival report greatly strengthens the 2003 findings," said Albain. "It is a major development in the battle against breast cancer."

The study also found that 55 percent of those taking paclitaxel alone stopped the therapy, due to disease progression, in contrast to only 38 percent of the combination drug group.
-end-
Co-authors of the study are K. S. Albain; S. Nag; G. Calderillo-Ruiz; J. P. Jordaan; A. Llombart; A. Pluzanska; M. Pawlicki; J.M. Reyes; A. S. Melmed; and J. O'Shaughnessy.

This study was funded by Eli Lilly and Company.

For more information on Loyola University Health System, log onto http://www.luhs.org.

The American Society of Clinical Oncology annual meeting at the Ernest N. Morial Convention Center, New Orleans, runs through June 8, 2004.

Loyola University Health System, a wholly owned subsidiary of Loyola University Chicago, includes Loyola University Medical Center (LUMC), 18 specialty and primary care centers in the western and southwestern suburbs, the Loyola Ambulatory Surgery Center at Oakbrook, the Loyola Imaging Center at Oakbrook Terrace, and serves as co-owner-operator of RML Specialty Hospital, a long-term-care facility for ventilator-dependent patients in suburban Hinsdale, Ill. LUMC, a private, academic health care institution, is nationally recognized for its specialty care and research in such areas as cancer, cardiology and cardiovascular surgery, pediatrics, neonatology and neurosciences, burn and trauma care and organ transplantation. The 73-acre campus in Maywood, Ill., includes the 523-bed licensed Loyola Hospital with a Level I trauma center, Russo Surgical Pavilion, Cardiovascular Institute, Cardinal Bernardin Cancer Center, Ronald McDonald Childrenfs Hospital of LUMC, Loyola University Chicago Stritch School of Medicine, the Loyola Outpatient Center, the regionfs largest burn unit and one of the Midwestfs largest and most comprehensive organ transplant programs.

Loyola University Health System

Related Breast Cancer Articles:

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
More Breast Cancer News and Breast Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.